Phase I/II Clinical Trial of Autologous Activated Platelet-Rich Plasma (aaPRP) in the Treatment of Severe Coronavirus Disease 2019 (COVID-19) Patients
Autor: | Irsyah Afini, Novy Fatkhurohman, Nurlaela Puspitaningrum, Imam Rosadi, Rita Novariani, Difky Ernanda, Wismo Reja Subroto, Siti Sobariah, Yuli Hertati, Louis Martin Christoffel, Karina Karina, Siti Rosidah, Iis Rosliana |
---|---|
Rok vydání: | 2021 |
Předmět: |
0301 basic medicine
medicine.medical_specialty Article Subject law.invention Proinflammatory cytokine 03 medical and health sciences 0302 clinical medicine law Internal medicine Pathology medicine RB1-214 Immunology and Allergy Adverse effect business.industry medicine.disease Intensive care unit Clinical trial Cytokine release syndrome 030104 developmental biology 030220 oncology & carcinogenesis Heart failure Platelet-rich plasma business Cytokine storm Research Article |
Zdroj: | International Journal of Inflammation, Vol 2021 (2021) International Journal of Inflammation |
ISSN: | 2042-0099 2090-8040 |
Popis: | Background. The outbreak of Coronavirus Disease 2019 (COVID-19) has been increasing rapidly. This disease causes an increase in proinflammatory cytokine production that leads to cytokine storm or cytokine release syndrome (CRS). Autologous activated platelet-rich plasma (aaPRP) contains various types of growth factors and anti-inflammatory cytokines that may have the potential to suppress CRS. This study of phase I/II trial was aimed to evaluate the safety and efficacy of aaPRP to treat severe COVID-19 patients. Methods. A total of 10 severe COVID-19 patients from Koja Regional Public Hospital (Koja RPH) were admitted to the intensive care unit (ICU). All patients received aaPRP administration three times. Primary outcomes involving the duration of hospitalization, oxygen needs, time of recovery, and mortality were observed. Secondary outcomes involving C-reactive protein (CRP), neutrophil, lymphocyte, and lymphocyte-to-CRP (LCR) and neutrophil-lymphocyte ratio (NLR) were analyzed. Results. All patients were transferred to the ICU with a median duration of 9 days. All patients received oxygen at enrollment and nine of ten patients recovered from the ICU and transferred to the ward room. There was one patient who passed away in the ICU due to heart failure. The results of secondary outcomes showed that CRP value and lymphocytes counts were significantly decreased while neutrophils, LCR, and NLR were slightly increased after aaPRP administration. Conclusions. Our results of the phase I/II trial demonstrated that the use of aaPRP in severe COVID-19 patients was safe and not associated with serious adverse events, which showed that aaPRP was a promising adjunctive therapy for severe COVID-19 patients. |
Databáze: | OpenAIRE |
Externí odkaz: | |
Nepřihlášeným uživatelům se plný text nezobrazuje | K zobrazení výsledku je třeba se přihlásit. |